Subject(s)
Cannabis , Commerce/legislation & jurisprudence , Controlled Substances/economics , Internet/economics , Public Health , Commerce/statistics & numerical data , Controlled Substances/supply & distribution , Internet/legislation & jurisprudence , Internet/statistics & numerical data , Postal Service/legislation & jurisprudence , Postal Service/statistics & numerical data , United StatesABSTRACT
On October 12, 2010, the President signed the Combat Methamphetamine Enhancement Act of 2010 (MEA). It establishes new requirements for mail-order distributors of scheduled listed chemical products. Mail-order distributors must now self-certify to DEA in order to sell scheduled listed chemical products at retail. Sales at retail are those sales intended for personal use; mail-order distributors that sell scheduled listed chemical products not intended for personal use, e.g., sale to a university, are not affected by the new law. This self-certification must include a statement that the mail-order distributor understands each of the requirements that apply under part 1314 and agrees to comply with these requirements. Additionally, mail-order distributors are now required to train their employees prior to self certification. DEA is promulgating this rule to incorporate the statutory provisions and make its regulations consistent with the new requirements and other existing regulations related to self-certification.
Subject(s)
Certification/legislation & jurisprudence , Commerce/legislation & jurisprudence , Drug and Narcotic Control/legislation & jurisprudence , Drug Packaging/legislation & jurisprudence , Ephedrine , Humans , Inservice Training/legislation & jurisprudence , Methamphetamine , Phenylpropanolamine , Postal Service/legislation & jurisprudence , Pseudoephedrine , United StatesABSTRACT
Counterfeit drugs are mainly distributed via the internet. On statement of the World Health Organization (WHO), one medicine out of ten ordered on the internet is counterfeit. Fighting against counterfeits needs close and international cooperation among manufacturers, wholesalers, pharmacies and agencies.
Subject(s)
Drug and Narcotic Control/legislation & jurisprudence , Fraud/legislation & jurisprudence , Illicit Drugs/legislation & jurisprudence , Internet/legislation & jurisprudence , Pharmaceutical Services/legislation & jurisprudence , Postal Service/legislation & jurisprudence , Prescription Drugs , Drug Contamination/legislation & jurisprudence , Drug-Related Side Effects and Adverse Reactions , Fraud/ethics , Germany , Humans , International Cooperation , Internet/ethics , Pharmaceutical Services/ethics , Postal Service/ethics , World Health OrganizationSubject(s)
Influenza A Virus, H1N1 Subtype/pathogenicity , Postal Service , Specimen Handling/methods , Virology/legislation & jurisprudence , Virology/methods , Animals , Canada , Centers for Disease Control and Prevention, U.S./legislation & jurisprudence , Humans , Influenza, Human/prevention & control , Influenza, Human/transmission , Influenza, Human/virology , Postal Service/legislation & jurisprudence , Safety Management/methods , United StatesSubject(s)
Drug and Narcotic Control/legislation & jurisprudence , Pharmaceutical Services/legislation & jurisprudence , Postal Service/legislation & jurisprudence , Commerce/legislation & jurisprudence , Delivery of Health Care/legislation & jurisprudence , Drug Prescriptions , Humans , Pharmacy Service, Hospital/legislation & jurisprudence , Pharmacy Service, Hospital/organization & administration , SpainABSTRACT
This regulation implements the new threshold requirements and mail order reporting requirements of the Methamphetamine Anti-Proliferation Act of 2000 (MAPA), which was enacted on October 17, 2000. DEA is amending its regulations to reduce the thresholds for pseudoephedrine and phenylpropanolamine for retail distributors and for distributors required to submit mail order reports. Also, DEA is amending its regulations to require mail order reports for certain export transactions. DEA is codifying exemptions from the mail order reporting requirements for certain distributions to nonregulated persons and certain export transactions. This rule is consistent with the intent of MAPA to prevent the diversion of drug products to the clandestine manufacture of methamphetamine and amphetamine, and simultaneously reduce the industry reporting burden.
Subject(s)
Drug Industry/legislation & jurisprudence , Drug and Narcotic Control/legislation & jurisprudence , Legislation, Drug , Methamphetamine/standards , Postal Service/legislation & jurisprudence , Ephedrine/standards , Health Care Sector , Humans , Phenylpropanolamine/standards , United States , United States Food and Drug AdministrationSubject(s)
Anthrax Vaccines/therapeutic use , Anthrax/drug therapy , Health Planning Guidelines , Aged , Aged, 80 and over , Centers for Disease Control and Prevention, U.S./legislation & jurisprudence , Contraindications , Female , Humans , Postal Service/legislation & jurisprudence , United States , United States Food and Drug Administration/legislation & jurisprudenceSubject(s)
Breast Neoplasms/therapy , Mass Screening , Philately , Postal Service , Prostatic Neoplasms/diagnosis , Research Support as Topic , Female , Health Policy , Health Promotion , History, 19th Century , History, 20th Century , Humans , Lobbying , Male , Philately/economics , Philately/history , Philately/legislation & jurisprudence , Postal Service/history , Postal Service/legislation & jurisprudence , Postal Service/organization & administration , United StatesABSTRACT
This article examines ways in which marketers of dietary supplements can make use of the "third-party literature" section of the Dietary Supplement Health and Education Act of 1994 (DSHEA). This provision permits persons or entities, other than manufacturers or distributors, to distribute to consumers certain publications in connection with the sale of particular supplements. These publications may include statements about the therapeutic benefits of such products without subjecting the products to regulation by the Food and Drug Administration (FDA) as unapproved new drugs. Specifically, this article addresses the following: Can a dietary supplement manufacturer or distributor send third-party literature about a dietary supplement to a customer in a mail order sales transaction? Can third-party literature be disseminated by mail with dietary supplement catalogues only? Can third-party literature be disseminated by sales representatives engaged in direct marketing of dietary supplements? Can third-party literature appear on the Internet? The answer appears to be affirmative in each of these situations.